<DOC>
	<DOCNO>NCT00192283</DOCNO>
	<brief_summary>The purpose study determine efficacy liquid formulation CAIVT culture confirm influenza illness healthy child age least 6 month le 36 month , attend day care center Europe . In addition , trial provide opportunity investigate effect CAIV-T acute otitis medium , healthcare resource utilization economic resource .</brief_summary>
	<brief_title>Trial Determine Safety Efficacy Influenza Virus Vaccine , Trivalent , Types A &amp; B , Live Cold- Adapted ( CAIV-T ) Healthy Children Attending Day Care Centers</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>age least 6 month le 36 month age time enrollment , attend day care least three day week , four hour day ; good health determine medical history , physical examination clinical judgement ; whose parent ( ) /legal guardian ( ) provide write informed consent nature study explain ; , along parent ( ) /legal guardian ( ) , available duration trial ( 8 month Â± 1 month ) ; whose parent ( ) /legal guardian ( ) , reach study staff postvaccination contact [ telephone , clinic home visit ] . whose parent ( ) /legal guardian ( ) perceive unavailable difficult contact evaluation study visit study period ; serious chronic disease ( e.g. , sign cardiac renal failure severe malnutrition ) , include progressive neurological disease ; Down 's syndrome know cytogenetic disorder ; know suspected disease immune system receive immunosuppressive therapy , include systemic corticosteroid ; receive blood product , include immunoglobulin , period six month prior vaccination conclusion study ; intent administer investigational vaccine agent one month prior enrollment conclusion study ; immunosuppressed immunocompromised individual living household ; , time prior entry study , receive dose influenza vaccine ( commercial investigational ) ; , two week prior entry study , receive dose influenza treatment ( commercial investigational ) ; document history hypersensitivity egg egg protein component study vaccine placebo ; clinically confirm respiratory illness wheeze within two week prior enrollment ; receive aspirin ( acetylsalicylic acid ) aspirincontaining product two week prior enrollment use anticipate study ; administer live virus vaccine within one month prior enrollment expect receive another live virus vaccine within one month vaccination study ; medical condition opinion investigator might interfere interpretation study result ; If criterion meet follow enrolment , subject exclude subsequent vaccine dosing . Note : A pregnant household member consider contraindication enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>36 Months</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>